{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:07:01Z","timestamp":1791486421963,"version":"4.3.4"},"reference-count":82,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>The genetic screening program for familial hypercholesterolemia (FH) in the Netherlands, which was embraced by the Dutch Ministry of Health from 1994 to 2014, has led to twenty years of identification of at least 1500 FH cases per year. Although funding by the government was terminated in 2014, the approach had proven its effectiveness and had built the foundation for the development of more sophisticated diagnostic tools, clinical collaborations, and new molecular-based treatments for FH patients. As such, the community was driven to continue the program, insurance companies were convinced to collaborate, and multiple approaches were launched to find new index cases with FH. Additionally, the screening was extended, now also including other heritable dyslipidemias. For this purpose, a diagnostic next-generation sequencing (NGS) panel was developed, which not only comprised the culprit LDLR, APOB, and PCSK9 genes, but also 24 other genes that are causally associated with genetic dyslipidemias. Moreover, the NGS technique enabled further optimization by including pharmacogenomic genes in the panel. Using such a panel, more patients that are prone to cardiovascular diseases are being identified nowadays and receive more personalized treatment. Moreover, the NGS output teaches us more and more about the dyslipidemic landscape that is less straightforward than we originally thought. Still, continuous progress is being made that underlines the strength of genetics in dyslipidemia, such as discovery of alternative genomic pathogenic mechanisms of disease development and polygenic contribution.<\/jats:p>","DOI":"10.3390\/genes12081168","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T10:47:46Z","timestamp":1627555666000},"page":"1168","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands"],"prefix":"10.3390","volume":"12","author":[{"given":"Linda C.","family":"Zuurbier","sequence":"first","affiliation":[{"name":"Department of Human Genetics, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep C.","family":"Defesche","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Amsterdam University Medical Center, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization Noncommunicable Diseases (2021, July 26). Fact Sheets 2021. Available online: www.who.int."},{"key":"ref_2","unstructured":"Eurostat Statistics (2021, July 26). Cardiovascular Diseases Statistics July 2018. Available online: www.ec.europa.eu."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients with Severe Hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","first-page":"25","article-title":"A Model of Care for Familial Hypercholesterolaemia: Key Role for Clinical Biochemistry","volume":"33","author":"Watts","year":"2012","journal-title":"Clin. Biochem. Rev."},{"key":"ref_5","unstructured":"Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, B. (2001). Familial Hypercholesterolemia. The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.atherosclerosis.2020.10.075","article-title":"Worldwide prevalence of familial hypercholesterolemia: Meta-analyses of 11 million subjects","volume":"315","author":"Beheshti","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of Familial Hypercholesterolemia among the General Population and Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., and Keech, A. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","article-title":"Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/CIRCULATIONAHA.106.671016","article-title":"Statin treatment in children with familial hypercholesterolemia: The younger, the better","volume":"116","author":"Rodenburg","year":"2007","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction among Different Therapeutic Interventions: A Systematic Review and Meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"ref_15","unstructured":"Reeskamp, L.F. (2021). Familial Hypercholesterolemia: Closing the Loop between Molecular Genetics and Personalized Medicine, in Vascular Medicine. [Ph.D. Thesis, University of Amsterdam]."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: A convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Miller, Y., and Tsimikas, S. (2009). Lipoprotein Oxidation and Modification, in Clinical Lipidology, Elsevier Inc.","DOI":"10.1016\/B978-141605469-6.50012-3"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0021-9150(98)90209-X","article-title":"Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention","volume":"140","author":"Wood","year":"1998","journal-title":"Atherosclerosis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/B978-0-12-387025-4.00004-2","article-title":"Hypobetalipoproteinemia: Genetics, biochemistry, and clinical spectrum","volume":"54","author":"Tarugi","year":"2011","journal-title":"Adv. Clin. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1194\/jlr.R001610","article-title":"The HDL hypothesis: Does high-density lipoprotein protect from atherosclerosis?","volume":"51","author":"Vergeer","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1161\/01.CIR.0000058166.99182.54","article-title":"Family history and cardiovascular risk in familial hypercholesterolemia: Data in more than 1000 children","volume":"107","author":"Wiegman","year":"2003","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/01.ATV.17.1.107","article-title":"Isolated Low HDL Cholesterol as a Risk Factor for Coronary Heart Disease Mortality","volume":"17","author":"Goldbourt","year":"1997","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"F15","DOI":"10.1093\/eurheartj\/sui038","article-title":"Raising HDL-cholesterol and lowering CHD risk: Does intervention work?","volume":"7","author":"Sheperd","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.aad3517","article-title":"Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease","volume":"351","author":"Zanoni","year":"2016","journal-title":"Science"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jacc.2018.10.072","article-title":"Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week","volume":"73","author":"Armitage","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/ATVBAHA.120.314050","article-title":"Novel Insights from Human Studies on the Role of High-Density Lipoprotein in Mortality and Noncardiovascular Disease","volume":"41","author":"Madsen","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/01.CIR.0000089506.12223.F1","article-title":"The metabolic syndrome: A practical guide to origins and treatment: Part II","volume":"108","author":"Wilson","year":"2003","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-Function Mutations inAPOC3and Risk of Ischemic Vascular Disease","volume":"371","author":"Nordestgaard","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute (2014). Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med., 371, 22\u201331.","DOI":"10.1056\/NEJMoa1307095"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2004.10.042","article-title":"Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: A parent\u2013offspring study","volume":"180","author":"Koeijvoets","year":"2005","journal-title":"Atherosclerosis"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Reeskamp, L., Tromp, T.R., Defesche, J.C., Grefhorst, A., Stroes, E.S., Hovingh, G.K., and Zuurbier, L. (2020). Next-generation sequencing to confirm clinical familial hypercholesterolemia. Eur. J. Prev. Cardiol., 2047487320942996.","DOI":"10.1177\/2047487320942996"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.atherosclerosis.2015.06.011","article-title":"Screening and treatment of familial hypercholesterolemia\u2014Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014)","volume":"241","author":"Besseling","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","article-title":"Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands","volume":"357","author":"Defesche","year":"2001","journal-title":"Lancet"},{"key":"ref_37","first-page":"281","article-title":"Principles and practice of mass screening for disease","volume":"65","author":"Wilson","year":"1968","journal-title":"Bol. Pficina Sanit. Panam."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000179","article-title":"Homozygous autosomal dominant hypercholesterolaemia: Prevalence, diagnosis, and current and future treatment perspectives","volume":"26","author":"Sjouke","year":"2015","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2020.07.022","article-title":"Electronic health records to facilitate continuous detection of familial hypercholesterolemia","volume":"310","author":"Pepplinkhuizen","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1602777","article-title":"Child\u2013Parent Familial Hypercholesterolemia Screening in Primary Care","volume":"375","author":"Wald","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Barale, C., Melchionda, E., Morotti, A., and Russo, I. (2021). PCSK9 Biology and Its Role in Atherothrombosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115880"},{"key":"ref_43","unstructured":"Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dungan, K., Grossman, A., Hershman, J.M., Hofland, J., and Kaltsas, G. (2000). Introduction to Lipids and Lipoproteins. Endotext, MDText.com, Inc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/er.2014-1062","article-title":"Hypertriglyceridemia in the Genomic Era: A New Paradigm","volume":"36","author":"Lewis","year":"2015","journal-title":"Endocr. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/humu.20256","article-title":"Update of the molecular basis of familial hypercholesterolemia in The Netherlands","volume":"26","author":"Fouchier","year":"2005","journal-title":"Hum. Mutat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"712","DOI":"10.7326\/0003-4819-148-9-200805060-00022","article-title":"Familial defective apolipoprotein B and familial hypobetalipoproteinemia in one family: Two neutralizing mutations","volume":"148","author":"Fouchier","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jacl.2020.01.007","article-title":"ABCG5 and ABCG8 genetic variants in familial hypercholesterolemia","volume":"14","author":"Reeskamp","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/humu.22215","article-title":"Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation","volume":"34","author":"Marduel","year":"2013","journal-title":"Hum. Mutat."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1194\/jlr.P055699","article-title":"Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France","volume":"57","author":"Wintjens","year":"2016","journal-title":"J. Lipid Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MOL.0000000000000734","article-title":"Recent advances in ABCG5 and ABCG8 variants","volume":"32","author":"Fong","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacl.2017.10.013","article-title":"The association between hypercholesterolemia and sitosterolemia, and report of a sitosterolemia kindred","volume":"12","author":"Brinton","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1210\/jc.2015-3874","article-title":"The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes","volume":"101","author":"Cenarro","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.amjcard.2012.02.052","article-title":"Resequencing CETP, LIPC and LIPG genes in Thai subjects with hyperalphalipoproteinemia","volume":"110","author":"Khovidhunkit","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1874192401711010084","article-title":"Interpreting the Mechanism of APOE (p.Leu167del) Mutation in the Incidence of Familial Hypercholesterolemia; An In-silico Approach","volume":"11","author":"Rashidi","year":"2017","journal-title":"Open Cardiovasc. Med. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.jacl.2017.08.017","article-title":"Incidental finding of severe hypertriglyceridemia in children. Role of multiple rare variants in genes affecting plasma triglyceride","volume":"11","author":"Buonuomo","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/01.ATV.13.5.720","article-title":"Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics","volume":"13","author":"Hegele","year":"1993","journal-title":"Arterioscler. Thromb. J. Vasc. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2016.08.014","article-title":"High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency","volume":"253","author":"Tani","year":"2016","journal-title":"Atherosclerosis"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1034\/j.1399-0004.1999.560212.x","article-title":"Physical activity modulates the effect of a lipoprotein lipase mutation (D9N) on plasma lipids and lipoproteins","volume":"56","author":"Boer","year":"1999","journal-title":"Clin. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ng0595-28","article-title":"A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis","volume":"10","author":"Reymer","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.hlc.2020.07.012","article-title":"Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry","volume":"30","author":"Pang","year":"2021","journal-title":"Heart Lung Circ."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12920-020-0669-2","article-title":"Six years\u2019 experience with LipidSeq: Clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias","volume":"13","author":"Dron","year":"2020","journal-title":"BMC Med. Genom."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jacc.2019.05.043","article-title":"Risk of Premature Atherosclerotic Disease in Patients with Monogenic versus Polygenic Familial Hypercholesterolemia","volume":"74","author":"Trinder","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2021.02.003","article-title":"Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia","volume":"321","author":"Reeskamp","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MOL.0000000000000741","article-title":"The clinical applicability of polygenic risk scores for LDL-cholesterol: Considerations, current evidence and future perspectives","volume":"32","author":"Cupido","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamacardio.2019.5954","article-title":"Association of Monogenic vs Polygenic Hypercholesterolemia with Risk of Atherosclerotic Cardiovascular Disease","volume":"5","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"003106","DOI":"10.1161\/CIRCGEN.120.003106","article-title":"Polygenic Risk Score for Low-Density Lipoprotein Cholesterol Is Associated with Risk of Ischemic Heart Disease and Enriches for Individuals With Familial Hypercholesterolemia","volume":"14","author":"Wu","year":"2021","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1373\/clinchem.2019.306738","article-title":"Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?","volume":"65","author":"Chan","year":"2019","journal-title":"Clin. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: A prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3389\/fgene.2020.01020","article-title":"PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis","volume":"11","author":"Guo","year":"2020","journal-title":"Front. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","article-title":"Diagnosis and treatment of familial hypercholesterolaemia","volume":"34","author":"Hovingh","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence Variations inPCSK9, Low LDL, and Protection against Coronary Heart Disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1358\/dot.2016.52.3.2440527","article-title":"PCSK9 inhibitors: Monoclonal antibodies for the treatment of hypercholesterolemia","volume":"52","author":"Paton","year":"2016","journal-title":"Drugs Today"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_81","unstructured":"(2021, July 26). EMA. Available online: https:\/\/www.ema.europa.eu."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia. Reply","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/8\/1168\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:36:35Z","timestamp":1760164595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/8\/1168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":82,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["genes12081168"],"URL":"https:\/\/doi.org\/10.3390\/genes12081168","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]}}}